# LL-37 in psoriasis: how skin cells respond to DNA | PepVault

Source: https://pepvault.app/research/ll-37-morizane-2012

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [LL-37](https://pepvault.app/research#ll-37)

Cell study · normal human keratinocytes

# LL-37 raised TLR9 and interferon output in human skin cells

Checked against the paper November 2026 Cell study [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In human skin cells, LL-37 made them react more strongly to DNA with an interferon immune response, a pattern also seen in psoriasis skin.

- **Kind:** Cell study
- **Studied in:** Normal human keratinocytes
- **Published:** 2012
- **Journal:** J Invest Dermatol

## What they tested

The team asked whether LL-37 lets skin cells react to DNA through TLR9 (Toll-like receptor 9), and whether this ties in with psoriasis.

## How the study was done

A lab study that compared skin from psoriasis lesions with normal skin, then exposed normal human keratinocytes (the main cells of the outer skin layer) grown in culture to LL-37, followed by TLR9 triggers such as CpG or genomic DNA.

<!--promo-->

PepVault for iPhone

## Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

In psoriasis lesions, human keratinocytes showed more TLR9, in the same areas where LL-37 levels were higher. In cultured normal human keratinocytes, LL-37 raised TLR9 levels, and cells primed with LL-37 then given CpG or genomic DNA made much more type I interferon (immune signaling proteins). Psoriasis lesions likewise held more interferon-beta than normal skin without LL-37. This response needed TLR9 but did not depend on LL-37 binding to the DNA.

## What it doesn’t show

Most of the work was in cultured skin cells, and the skin comparisons show patterns rather than cause. LL-37 was not tested as a treatment in people or animals.

## The paper

Morizane et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012.

- [PubMed (PMID 21850017)](https://pubmed.ncbi.nlm.nih.gov/21850017/)
- [The paper (DOI 10.1038/jid.2011.259)](https://doi.org/10.1038/jid.2011.259)

## The compound

- [LL-37: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/ll-37)
- [LL-37 dose guide](https://pepvault.app/lab/dosage/ll-37)

## With this study

### LL-37

- [LL-37: the full reference](https://pepvault.app/peptides/ll-37)
- [LL-37 dose guide](https://pepvault.app/lab/dosage/ll-37)

### Mixing charts

- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/ll-37-5mg)

### Studies

- [LL-37 cream: bigger granulation gains in diabetic foot ulcers](https://pepvault.app/research/ll-37-miranda-2023)
- [LL-37: no healing gain over placebo for venous leg ulcers overall](https://pepvault.app/research/ll-37-heal-ll-37-2021)
- [LL-37 drove IL-1β and IL-18 release from human and murine macrophages](https://pepvault.app/research/ll-37-kahlenberg-2013)
- [All 4 studies](https://pepvault.app/research#ll-37)

### Compared with

- [KPV vs LL-37](https://pepvault.app/peptides/compare/kpv-vs-ll-37)
- [Thymosin Alpha-1 vs LL-37](https://pepvault.app/peptides/compare/thymosin-alpha-1-vs-ll-37)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

## More studies on LL-37

- [LL-37 cream: bigger granulation gains in diabetic foot ulcers](https://pepvault.app/research/ll-37-miranda-2023) Randomized trial · people · 2023
- [LL-37: no healing gain over placebo for venous leg ulcers overall](https://pepvault.app/research/ll-37-heal-ll-37-2021) Randomized trial · people · 2021
- [LL-37 drove IL-1β and IL-18 release from human and murine macrophages](https://pepvault.app/research/ll-37-kahlenberg-2013) Cell study · human and murine macrophages · 2013
- [Every study on LL-37](https://pepvault.app/research#ll-37)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### LL-37

- [LL-37: the full reference](https://pepvault.app/peptides/ll-37)
- [LL-37 dose guide](https://pepvault.app/lab/dosage/ll-37)

### Mixing charts

- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/ll-37-5mg)

### Studies

- [LL-37 cream: bigger granulation gains in diabetic foot ulcers](https://pepvault.app/research/ll-37-miranda-2023)
- [LL-37: no healing gain over placebo for venous leg ulcers overall](https://pepvault.app/research/ll-37-heal-ll-37-2021)
- [LL-37 drove IL-1β and IL-18 release from human and murine macrophages](https://pepvault.app/research/ll-37-kahlenberg-2013)
- [All 4 studies](https://pepvault.app/research#ll-37)

### Compared with

- [KPV vs LL-37](https://pepvault.app/peptides/compare/kpv-vs-ll-37)
- [Thymosin Alpha-1 vs LL-37](https://pepvault.app/peptides/compare/thymosin-alpha-1-vs-ll-37)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

<!--promo-->

PepVault for iPhone

## Taking LL-37? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on LL-37](https://pepvault.app/research#ll-37)

## The library

- [LL-37](https://pepvault.app/peptides/ll-37)
- [LL-37 dose guide](https://pepvault.app/lab/dosage/ll-37)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
